Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

Phase 3 Completed 20 enrolled The University of Texas Health Science Center, Houston Cures Within Reach · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.

Timeline

Start: 2019-08-05
Primary completion: 2022-11-11
Completion: 2022-11-11

Outcome

Missed primary endpoint

paper DM/Q did not demonstrate significant benefits in managing irritability compared to placebo. PMID 41499296 ↗

paper with no statistically significant differences between groups. PMID 41499296 ↗

Publications

Zadegan SA, Calderon O, Karagas N, Patino J, Dongarwar D, Duncan B, Teixeira AL, Rocha NP, Furr Stimming E. Assessing the efficacy of dextromethorphan/quinidine in treating irritability in Huntington's disease. J Huntingtons Dis. 2026 Jan 7:18796397251411112. doi: 10.1177/18796397251411112. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dextromethorphan/quinidine	Unknown	10 mg	—
Subject	Dextromethorphan/quinidine	Unknown	20 mg	—